India's benchmark Nifty 50 index is set to open marginally higher on Thursday after sinking into correction territory in the ...

The development reflects the company's strategy to raise funds and expand its market position. CIPLA Cipla is in focus due to ...

Stay informed with the Cipla Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a ...

Cipla Ltd. announced on Wednesday that the company received eight observations from the US Food and Drug Administration for ...

Following an inspection of its Bengaluru facility, Cipla has received 8 observations in Form 483 from the US Food and Drug ...

Cipla’s FDA-compliant facilities and its investments in US-based units place it in a strong position to weather potential ...

Tilak Varma slams ton as India take 2-1 lead against South Africa with 11-run win in third T20I 23-year-old lecturer's organs ...

Here's the complete list of investment and trading ideas for the day. Buy Garden Reach shares in the cash segment for a ...

Shivam Puri, CEO, Cipla Health, discusses the brand proposition of Prolyte ORS, shares strategy that helped brand achieve Rs ...

Cipla , India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, ...

GIFT Nifty was trading marginally up, 5 points or 0.02% at 23,649 indicating a muted start for domestic indices. Here are the top stocks to watch for the day.

(Reuters) -Cipla, India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, driven by higher sales of its respiratory and cancer drugs ...